Considering a broader global view of the life sciences industry, 2018 was another strong-performing year for M&A activity, where with the UK specifically, key highlights include:
– The total number of UK life sciences vacancies rose by 20%.
– CRO’s have grown significantly over 2018, with activity up over 25%. IQVIA specifically has seen a large increase.
– Finally, vacancies for clinical roles have seen a 40% rise over 2018, with clinical projects being a key area.
Key trends emerging include:
2018 was a peak month for vacancies across the
EU27, with volumes reaching the highest point since February.
Vacancies for Quality Control remain the biggest area of hiring within QA roles, with volumes up 30% on last year.
Overall, 20% of all posted vacancies are located in Germany, which means it remains the largest market in European pharmaceuticals with activity up 7% year on year.
Other key snapshots include:
– When analysed by country, Belgium and Switzerland have seen significant increases in activity this year so far
– By sector, whilst still small by comparison to others, proportionately there has been a big uplift within biotechnology
– GSK is a company to watch, with hiring up by over 100% on last year for regulatory professionals.
With the UK now about to leave the EU, the
pressure on procurement and supply chains is likely
to intensify shortly, as businesses re-organise to the
Also factor that in a recent survey of Chief Procurement Officers by Deloitte, 51% of leaders believe their current teams do not have sufficient skills and capabilities to deliver on their procurement strategy.
Within large pharmaceuticals companies, hiring for procurement professionals has actually been falling. What has been driving this change?
The UK has seen steady growth in medical affairs positions since 2016, with the average for vacancies in 2018 so far rising 14.2% from 2017, and figures rising 13.2% in 2017.
It is worth noting that when looking across continental Europe, growth has outpaced that of the UK, with vacancies up 27% in Benelux and 41% in Germany for example.
Whilst the UK has had the most medical vacancies for Q1 2018 to what extent will the UK’s pharmaceutical industry manage to continue this trend if there is a hard Brexit?